Rapid reduction of glucocorticoid (GC) doses to 7.5 mg/day or less within 6 months may not worsen renal outcomes or increase relapse in patients with proliferative lupus nephritis (LN), recent study ...

Early detection and new biomarkers are changing how we manage acute kidney injury—and its link to chronic kidney disease.

Patients who develop LN within 1 to 5 years after SLE onset may face poorer renal outcomes compared with those who develop the disease earlier.

Belimumab, a monoclonal antibody, added to standard therapy may treat a broader range of patients with lupus nephritis than previously appreciated.

A new trial finds that intravenous immunoglobulin stabilises kidney function and slows damage in patients with chronic ...

A top ERA abstract presents a biomarker-based model that non-invasively estimates kidney fibrosis in patients with IgA ...

Background Lupus nephritis (LN) is a common manifestation of systemic lupus erythematosus (SLE), with 10–30% progressing to end-stage renal disease (ESRD) and requiring dialysis. Kidney ...